Quotient Bioresearch has announced an educational webinar series entitled '14C Enabled Drug Development in Pharmaceutical Research and Development'.
The webinars will consist of scientific presentations from industry experts focused on a broad range of drug development activities that can be enhanced by 14C radiolabelled studies.
The webinar series begins on 27 April and runs during May and early June 2010.
Each of the four webinars will cover specific topics: metabolism; species and interspecies dependent metabolism; IVPK and absolute bio-availability; and Quotient's Synthesis-to-Clinic platform.
Each webinar will run twice a day at the following times: 07:00 and 09:00 Pacific Time/10:00 and 12:00 Eastern Time/15:00 and 17:00 UK.
Webinar One will be held on 27 April and presented by Prof Tim Baillie, dean of the school of pharmacy at the University of Washington, and formerly global vice-president - drug metabolism and pharmacokinetics with Merck.
Baillie will discuss how the Food and Drug Administration's MIST and ICH M3(r2) guidelines encourage metabolism investigations earlier than ever in drug development.
The presentation will look at how industry is approaching this through innovative study designs and use of new technologies such as accelerator mass spectrometry and Orbitrap to enhance the information that can be generated during metabolism studies.
The webinar will explore future approaches to conducting metabolism studies.
Webinar Two will be held on 11 May 2010 and presented by Prof Alan Rettie, chairman - department of medicinal chemistry at the University of Washington.
Rettie will explore the impact of inter-species differences on metabolism studies and the impact of inter-species genetic polymorphisms on metabolism.
The presentation will also provide case studies to highlight notable cases of metabolism directing the individual response.
Webinar Three will be held on 25 May 2010 and presented by Dr Bob Ings, RMI Pharmacokinetics and ex-vice-president DMPK Roche Palo Alto.
Ings will illustrate how the routine use of IV microtracer dosing can enhance drug development and discuss what the data offer in terms of understanding absolute bioavailability, clearance characteristics and drug performance.
Webinar Four will be held on 8 June and will explain how the themes discussed in the first three webinars can be addressed by services available through Quotient's Synthesis-to-Clinic platform.
Case histories will be used to showcase recent applications of the Synthesis-to-Clinic platform and there will also be a QandA of key topics of interest raised throughout the webinar series.
